These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17875748)

  • 1. Progressive thoughts about progressive disease.
    Shah NP
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5229-31. PubMed ID: 17875748
    [No Abstract]   [Full Text] [Related]  

  • 2. Linking the hematopoietic microenvironment to imatinib-resistant Ph+ B-ALL.
    Dorshkind K; Witte ON
    Genes Dev; 2007 Sep; 21(18):2249-52. PubMed ID: 17875661
    [No Abstract]   [Full Text] [Related]  

  • 3. Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.
    Strout MP; Schatz DG
    Cancer Cell; 2009 Sep; 16(3):174-6. PubMed ID: 19732715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
    Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
    Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
    [No Abstract]   [Full Text] [Related]  

  • 5. The advent of targeted therapeutics and implications for pathologists.
    Hess JL
    Am J Clin Pathol; 2002 Mar; 117(3):355-7. PubMed ID: 11888074
    [No Abstract]   [Full Text] [Related]  

  • 6. Imatinib.
    de Kogel CE; Schellens JH
    Oncologist; 2007 Dec; 12(12):1390-4. PubMed ID: 18165615
    [No Abstract]   [Full Text] [Related]  

  • 7. [Targeted anticancer drugs and their development].
    Kervinen J; Gahmberg CG
    Duodecim; 2004; 120(19):2323-30. PubMed ID: 15565985
    [No Abstract]   [Full Text] [Related]  

  • 8. [Molecular treatment of cancer. Imatinib].
    Lopez M
    Clin Ter; 2001; 152(6):399-407. PubMed ID: 11865537
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
    Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
    Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
    Minami Y; Naoe T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the offensive.
    Abbott A
    Nature; 2002 Apr; 416(6880):470-4. PubMed ID: 11932714
    [No Abstract]   [Full Text] [Related]  

  • 12. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
    Engelman JA; Settleman J
    Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia.
    Park TS; Cheong JW; Kim SJ; Lee KW; Song J; Lee KA; Suh B; Song S; Choi JR
    Cancer Genet Cytogenet; 2009 Apr; 190(1):46-8. PubMed ID: 19264234
    [No Abstract]   [Full Text] [Related]  

  • 14. Resistance and relapse with imatinib in CML: causes and consequences.
    Deininger M
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S11-S21. PubMed ID: 18397677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmazie in unserer Zeit 5/2008].
    Dingermann T; Laufer S; Winckler T
    Pharm Unserer Zeit; 2008; 37(5):349. PubMed ID: 18729281
    [No Abstract]   [Full Text] [Related]  

  • 16. Unexplored pharmacokinetic opportunities with microdosing in oncology.
    Sparreboom A
    Clin Cancer Res; 2007 Jul; 13(14):4033-4. PubMed ID: 17634525
    [No Abstract]   [Full Text] [Related]  

  • 17. Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance.
    Pocaly M; Lagarde V; Etienne G; Dupouy M; Lapaillerie D; Claverol S; Vilain S; Bonneu M; Turcq B; Mahon FX; Pasquet JM
    Proteomics; 2008 Jun; 8(12):2394-406. PubMed ID: 18563733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in molecular targets and cancer therapeutics.
    Westwell AD
    Drug Discov Today; 2004 Mar; 9(5):207-9. PubMed ID: 14980538
    [No Abstract]   [Full Text] [Related]  

  • 19. Cancer therapy: new drugs are emerging based on molecular targeting but still many challenges.
    Altucci L; Balducci L; Irminger-Finger I
    Int J Biochem Cell Biol; 2007; 39(7-8):1278-9. PubMed ID: 17548227
    [No Abstract]   [Full Text] [Related]  

  • 20. Catastrophic tumour lysis syndrome following single dose of imatinib.
    Keane C; Henden A; Bird R
    Eur J Haematol; 2009 Mar; 82(3):244-5. PubMed ID: 19067739
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.